GB0218234D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB0218234D0
GB0218234D0 GB0218234A GB0218234A GB0218234D0 GB 0218234 D0 GB0218234 D0 GB 0218234D0 GB 0218234 A GB0218234 A GB 0218234A GB 0218234 A GB0218234 A GB 0218234A GB 0218234 D0 GB0218234 D0 GB 0218234D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0218234A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB0218234A priority Critical patent/GB0218234D0/en
Publication of GB0218234D0 publication Critical patent/GB0218234D0/en
Priority to AR20030102790A priority patent/AR040778A1/en
Priority to TW092121286A priority patent/TWI323265B/en
Priority to CA2494008A priority patent/CA2494008C/en
Priority to IL16547803A priority patent/IL165478A0/en
Priority to BR0312456-8A priority patent/BR0312456A/en
Priority to PT37841954T priority patent/PT1526868E/en
Priority to DK03784195.4T priority patent/DK1526868T3/en
Priority to MYPI20032945A priority patent/MY148409A/en
Priority to AU2003255390A priority patent/AU2003255390B2/en
Priority to SI200332328T priority patent/SI1526868T1/en
Priority to PL375405A priority patent/PL211014B1/en
Priority to US10/523,295 priority patent/US7612183B2/en
Priority to PCT/EP2003/008749 priority patent/WO2004014953A2/en
Priority to NZ537123A priority patent/NZ537123A/en
Priority to KR1020057002132A priority patent/KR101078459B1/en
Priority to CNB03818477XA priority patent/CN100542607C/en
Priority to EP03784195.4A priority patent/EP1526868B1/en
Priority to ES03784195.4T priority patent/ES2440652T3/en
Priority to MXPA05001468A priority patent/MXPA05001468A/en
Priority to JP2004526901A priority patent/JP4528121B2/en
Priority to IS7576A priority patent/IS7576A/en
Priority to IL165478A priority patent/IL165478A/en
Priority to NO20045323A priority patent/NO333876B1/en
Priority to HK05109282.3A priority patent/HK1077206A1/en
Priority to US12/060,555 priority patent/US8071731B2/en
Priority to CY20141100027T priority patent/CY1114919T1/en
Ceased legal-status Critical Current

Links

GB0218234A 2002-08-06 2002-08-06 Antibodies Ceased GB0218234D0 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GB0218234A GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies
AR20030102790A AR040778A1 (en) 2002-08-06 2003-08-04 ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY).
TW092121286A TWI323265B (en) 2002-08-06 2003-08-04 Antibodies
JP2004526901A JP4528121B2 (en) 2002-08-06 2003-08-05 Anti-myelin-related glycoprotein (MAG) antibody
US10/523,295 US7612183B2 (en) 2002-08-06 2003-08-05 Humanised anti-mag antibody or functional fragment thereof
CNB03818477XA CN100542607C (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (MAG) antibody
BR0312456-8A BR0312456A (en) 2002-08-06 2003-08-05 Altered antibody or functional fragment thereof, polynucleotide, polynucleotide sequence, pharmaceutical composition, methods of treatment or prophylaxis of stroke and other neurological diseases / disorders in a human, inhibiting neurodegeneration and / or promoting functional recovery and promoting axonal development, and use of an anti-mag antibody
PT37841954T PT1526868E (en) 2002-08-06 2003-08-05 Anti-mag humanised antibodies and their uses for treating stroke
DK03784195.4T DK1526868T3 (en) 2002-08-06 2003-08-05 HUMANIZED ANTI-MAG ANTIBODIES AND THEIR APPLICATIONS FOR TREATING CASES
MYPI20032945A MY148409A (en) 2002-08-06 2003-08-05 Anti-mag antibodies
AU2003255390A AU2003255390B2 (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (MAG) antibodies
SI200332328T SI1526868T1 (en) 2002-08-06 2003-08-05 Anti-mag humanised antibodies and their uses for treating stroke
PL375405A PL211014B1 (en) 2002-08-06 2003-08-05 Antibodies
CA2494008A CA2494008C (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (mag) antibodies
PCT/EP2003/008749 WO2004014953A2 (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (mag) antibodies
NZ537123A NZ537123A (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (MAG) antibodies and the use thereof to treat stroke and other neurological disorders
KR1020057002132A KR101078459B1 (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoproteinmag antibodies
IL16547803A IL165478A0 (en) 2002-08-06 2003-08-05 Anti-myelin associated ghycoprotein (MAG) antibodies
EP03784195.4A EP1526868B1 (en) 2002-08-06 2003-08-05 Anti-mag humanised antibodies and their uses for treating stroke
ES03784195.4T ES2440652T3 (en) 2002-08-06 2003-08-05 Humanized anti-MAG antibodies and their uses for stroke treatment
MXPA05001468A MXPA05001468A (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (mag) antibodies.
IL165478A IL165478A (en) 2002-08-06 2004-11-30 Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody
IS7576A IS7576A (en) 2002-08-06 2004-11-30 Anti-myelin-linked glycoprotein (MAG) antibodies
NO20045323A NO333876B1 (en) 2002-08-06 2004-12-03 Humanized antibody as well as pharmaceutical preparation.
HK05109282.3A HK1077206A1 (en) 2002-08-06 2005-10-20 Anti-mag humanised antibodies and their uses for treating stroke
US12/060,555 US8071731B2 (en) 2002-08-06 2008-04-01 Humanised anti-MAG antibody or functional fragment thereof
CY20141100027T CY1114919T1 (en) 2002-08-06 2014-01-14 ANTI-MAG MANUFACTURED ANTIBODIES AND THEIR USES FOR TREATMENT OF THE Cerebral Palsy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0218234A GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies

Publications (1)

Publication Number Publication Date
GB0218234D0 true GB0218234D0 (en) 2002-09-11

Family

ID=9941819

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0218234A Ceased GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies

Country Status (1)

Country Link
GB (1) GB0218234D0 (en)

Similar Documents

Publication Publication Date Title
EP1494693A4 (en) Cripto-specific antibodies
PL375405A1 (en) Antibodies
HK1213007A1 (en) Anti-avb6 antibodies v6
EP1616881A4 (en) Anti-mpl antibodies
IL175608A0 (en) Antibodies
PT1599504E (en) Modified antibody
AU2003217912A8 (en) Antibody optimization
EP1432444A4 (en) Anti-a-beta antibodies
HK1074206A1 (en) Anti-trail-r antibodies
GB0228210D0 (en) Single chain antibodies
GB0208331D0 (en) Proteins
GB0209884D0 (en) Proteins
EP1677112A4 (en) Immunoassay
GB0305448D0 (en) Immunoassay
EP1487874A4 (en) Falp proteins
GB0306618D0 (en) Antibody
GB0226878D0 (en) Antibodies
PL376318A1 (en) Protein modification
AU2003270055A8 (en) Neurotransmission-associated proteins
AU2003300785A8 (en) Carbohydrate-associated proteins
GB0218230D0 (en) Antibodies
HK1072381A1 (en) Cripto-specific antibodies cripto-specific
GB0218232D0 (en) Antibodies
GB0218235D0 (en) Antibodies
GB0218229D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)